

Q1 20\_21 Performance In Delivering

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
45302	18/WS/0172	251636	A randomized, open-label, multi-center, controlled clinical study to compare MAR-CUTIS with Dermabond Advanced in closure of surgical incisions and lacerations =15cm	Number Agreed	1	1	Date Agreed	22/07/2019	1	22/07/2019	1	Recruitment Finished	
45303	19/SC/0204	260266	A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Coliti	Number Agreed	5	5	Date Agreed	31/12/2021	0	21/08/2019	0	Withdrawn By Host	Abandoned due to local capacity issues
45304	19/WM/0204	261470	A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active	Number Agreed	5	5	Date Agreed	05/12/2021	0	21/08/2019	0	Withdrawn By Host	Abandoned due to local capacity issues
45305	19/YH/0072	257713	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 CO-ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODF	Range Agreed	0	0	Date Agreed	22/11/2019	0	22/11/2019	0	Recruitment Finished	No eligible patients
45306	18/LO/0381	240085	A Phase II/III Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics thera	Number Agreed	2	2	Date Agreed	31/05/2020	2	04/02/2020	2	Recruitment Finished	
45307	19/LO/0397	243173	A Phase 2/3, Randomized, Double-blind, Placebo-and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	Number Agreed	1	1	Date Agreed	01/05/2021	0	06/02/2020	0	Withdrawn By Host	Barnsley have withdrawn from the study at this time due to concerns regarding the IMP preparation
45308	17/NE/0351	235420	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE DIAGNOSIS OF PROSTATE CANCER	Number Agreed	13	13	Date Agreed	31/03/2020	13	31/03/2020	13	Recruitment Finished	
45309	18/NE/0312	245315	A Phase 3 Randomized, Double-blind, Multi-Centre, Long-term Extension Study Investigating The Efficacy And Safety Of PF-04965842, With Or Without Topical Medications, Administered To Subjects 12 years And Over With Moderate-To-Severe Atopic Dermatiti	Number Agreed	1	1	Date Agreed	07/07/2020	1	22/11/2019	1	Recruitment Finished	early finish